{
    "Clinical Trial ID": "NCT00971737",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Cyclophosphamide and Vaccine Only",
        "  Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.",
        "  allogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally",
        "  cyclophosphamide: Given IV",
        "INTERVENTION 2: ",
        "  Cyclophosphamide, Vaccine and Trastuzumab",
        "  Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.",
        "  allogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally",
        "  trastuzumab: Given IV",
        "  cyclophosphamide: Given IV"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed adenocarcinoma of the breast",
        "  Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC",
        "  Stage IV disease",
        "  Must not be eligible for therapy of known curative potential for metastatic breast cancer",
        "  Measurable or evaluable disease",
        "  Stable CNS disease allowed provided that it's adequately treated and not under active treatment",
        "  Hormone receptor status not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Menopausal status not specified",
        "  ECOG performance status 0-1",
        "  ANC > 1,000/mm^3",
        "  Platelets > 100,000/mm^3",
        "  Serum bilirubin < 2.0 mg/dL (unless due to Gilbert syndrome)",
        "  AST and ALT < 2 times upper limit of normal (ULN)",
        "  Alkaline phosphatase < 5 times ULN",
        "  Serum creatinine < 2.0 mg/dL",
        "  Ejection fraction normal by MUGA OR  50% by echocardiogram",
        "  Not pregnant or nursing",
        "  Fertile patients must use effective contraception",
        "  HIV negative",
        "  Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids allowed",
        "  No prior or concurrent autoimmune disease requiring management with systemic immunosuppression, including any of the following:",
        "  Inflammatory bowel disease",
        "  Systemic vasculitis",
        "  Scleroderma",
        "  Psoriasis",
        "  Multiple sclerosis",
        "  Hemolytic anemia or immune-mediated thrombocytopenia",
        "  Rheumatoid arthritis",
        "  Systemic lupus erythematosus",
        "  Sjogren syndrome",
        "  Sarcoidosis",
        "  Other rheumatologic disease",
        "  No other malignancies within the past 5 years, except carcinoma in situ of the cervix, superficial nonmelanoma skin cancer, superficial bladder cancer, or tamoxifen-related endometrial cancer that has been adequately treated",
        "  No active major medical or psychosocial problems that could be complicated by study participation",
        "  No symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest",
        "  No uncontrolled medical problems",
        "  No evidence of active acute or chronic infection",
        "  No known severe hypersensitivity to trastuzumab, except mild to moderate infusion reactions that are easily managed and do not recur",
        "  No allergy to corn",
        "  PRIOR CONCURRENT THERAPY:",
        "  See Disease Characteristics",
        "  More than 28 days since prior and no other concurrent chemotherapy, radiation therapy, or biologic therapy (except trastuzumab)",
        "  Concurrent endocrine therapy and supportive therapy with bisphosphonates allowed",
        "  More than 28 days since prior and no other concurrent participation in an investigational new drug trial",
        "  More than 28 days since prior and no other concurrent systemic oral steroids",
        "  Topical, ocular, and nasal steroids allowed",
        "  No prior vaccination with the allogeneic GM-CSF-secreting breast tumor vaccine"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Toxicity as Assessed by Number of Grade 3 or 4 Adverse Events",
        "  Number of grade 3 or 4 nonhematologic toxicity (except alopecia), or any grade 4 hematologic toxicity as defined by NCI CTCAE v3.0",
        "  Time frame: 3 years",
        "Results 1: ",
        "  Arm/Group Title: Cyclophosphamide and Vaccine Only",
        "  Arm/Group Description: Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.",
        "  allogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally",
        "  cyclophosphamide: Given IV",
        "  Overall Number of Participants Analyzed: 28",
        "  Measure Type: Number",
        "  Unit of Measure: adverse events  0",
        "Results 2: ",
        "  Arm/Group Title: Cyclophosphamide, Vaccine and Trastuzumab",
        "  Arm/Group Description: Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.",
        "  allogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally",
        "  trastuzumab: Given IV",
        "  cyclophosphamide: Given IV",
        "  Overall Number of Participants Analyzed: 30",
        "  Measure Type: Number",
        "  Unit of Measure: adverse events  2"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/30 (0.00%)",
        "Adverse Events 2:",
        "  Total: "
    ]
}